1
|
Mentuccia L, Gelibter A, Sperduti I, D'Onofrio L, Botticelli A, Vici P, Cassano A, Moscetti L, Carbognin L, Graziano V, Barchiesi G, Rossi E, Cursano M, Pizzuti L, Paris I, Vaccaro A, Fabbri A, Rossi L, Samaritani R, Sarmiento R, Gamucci T. Efficacy of pertuzumab in combination with trastuzumab and a taxane in in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Pizzuti L, Sperduti I, Michelotti A, Omarini C, Gamucci T, Natoli C, D'Onofrio L, Giotta F, Ficorella C, Laudadio L, Cassano A, Marchetti P, Adamo V, Mauri M, Scinto A, Zampa G, Fabbri A, Mentuccia L, Barni S, Vici P. Trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC): Results from a multicenter retrospective analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
3
|
Pizzuti L, Sperduti I, Michelotti A, Omarini C, Gamucci T, Natoli C, D'Onofrio L, Giotta F, Ficorella C, Laudadio L, Cassano A, Marchetti P, Adamo V, Mauri M, Scinto A, Zampa G, Fabbri A, Mentuccia L, Barni S, Vici P. Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Moscetti L, Vici P, Sperduti I, Palleschi M, Magri V, Iezzi L, Fabbri M, D'Onofrio L, Mentuccia L, Vaccaro A, Trenta P, Ramponi S, Roma C, Ruggeri E. Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Iezzi L, Mentuccia L, Vici P, Natoli C, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Magnolfi E, Sergi D, Gamucci T. Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: a restrospective multicenter observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Pizzuti L, Barba M, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Fancelli S, Grassadonia A, Michelotti A, Pescarmona E, Perracchio L, Maugeri-Saccà M, Vici P. Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Mentuccia L, Fabi A, Cassano A, Vici P, Michelotti A, Sperduti I, Sarobba G, Marchetti P, Scognamiglio M, Vaccaro A, Rossi E, Pellegrini D, Nicoletta D, Pellegrino A, Sini V, Pizzuti L, Palleschi M, Moscetti L, Jamara G, Ciancola F, Gamucci T. Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Barni S, Fontanella C, Del Mastro L, Livraghi L, Morritti M, Pizzuti L, Michelotti A, Lutrino E, Ciccarese M, Musolino A, Quercia S, Garrone O, Pellegrino A, Pistelli M, Martella F, Iezzi L, Mentuccia L, Latorre A, D'Onofrio L, Porcu L. 1849 Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30799-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Gamucci T, Mentuccia L, Vici P, Iezzi L, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Sergi D, Magnolfi E, Natoli C. 1950 Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30898-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Pizzuti L, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Mentuccia L, Vaccaro A, Trenta P, Seminara P, Rapposelli I, Sini V, Santini D, Sperduti I, Marchetti P, Vici P. Her2-Positive Early Breast Cancer in the Pre-Trastuzumab and Trastuzumab Eras: a Triple Positive Subgroup Analysis of a Multicenter Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Mentuccia L, Vici P, Sperduti I, Pizzuti L, Moscetti L, Vaccaro A, Quadrini S, Magnolfi E, Fabbri M, Zampa G, Giampaolo M, Sergi D, Narducci F, Sacca MM, Gamucci T. Fact- B and Esas in Metastatic Breast Cancer (Mbc) Patients (Pts) Treated with Eribulin: Results of a Multicenter Prospective Observational Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu350.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, Pavese I, Sperduti I, Vaccaro A, Vici P. Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. J Cancer Res Clin Oncol 2013; 140:221-6. [PMID: 24292401 PMCID: PMC3895217 DOI: 10.1007/s00432-013-1556-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Accepted: 11/18/2013] [Indexed: 01/05/2023]
Abstract
PURPOSE Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥ 2 diarrhea incidence and, secondarily, treatment efficacy. PATIENTS AND METHODS Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m(2), starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. RESULTS Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. CONCLUSION The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.
Collapse
Affiliation(s)
- T Gamucci
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100, Frosinone, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139:853-60. [PMID: 23411686 PMCID: PMC3625404 DOI: 10.1007/s00432-013-1388-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 01/29/2013] [Indexed: 01/03/2023]
Abstract
PURPOSE Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, accordingly with some prognostic biological factors. METHODS We retrospectively evaluated 900 node-negative patients (pT1a, b, c) surgery treated between 2000 and 2009 in four Italian oncologic centers. We defined 3 different cohorts: ER positive (ER+); Her-2 positive (Her-2+); and triple negative (TN). RESULTS pT1a was seen in 7.6% of patients, 37.7 % pT1b, 54.8 % pT1c. Concerning the 3 different cohorts, 58.2 % were ER+; 10.8 % were Her-2+; 8.2 % were TN. Overall, chemotherapy was given to 3.0 %, 27.2 %, 69.8 % of pT1a, b, c, respectively, and to 22.7 %, 58.8 %, 68.9 % of ER+, Her-2+, TN subgroups. At a median follow-up of 67 months, 5-year DFS was 96.3 %, 89.2 %, 89.4 % in pT1a, b, c, respectively (100 %, 93.6 %, 89.8 % in ER+; 100 %, 78.7 %, 85.0 % in Her-2+; 100 %, 76.8 %, 85.2 % in TN) (p = ns). At multivariate analysis, histologic grade and Ki-67 resulted independent prognostic factors. Overall, 5-year OS was 98 %, without differences among pT1a, b, c, or among the 3 cohorts. CONCLUSIONS Overall, 5-year DFS was very favorable in this series of small, node-negative breast cancers, but Her-2+ and TN cohorts have a higher recurrence rate than ER+ cohort (p < 0.0001); pT1c, but also pT1b, in Her-2+ and TN subgroups, have a worse outcome, and effective chemotherapy treatment should be considered in these unfavorable subgroups.
Collapse
Affiliation(s)
- T. Gamucci
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - A. Vaccaro
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - F. Ciancola
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Pizzuti
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - I. Sperduti
- Department of Biostatistics, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - L. Moscetti
- Medical Oncology Unit, Belcolle Hospital, Strada Sammartinese 1, 01100 Viterbo, Italy
| | - F. Longo
- Medical Oncology Unit A, La Sapienza University of Rome, Viale del Policlinico 161, 00161 Rome, Italy
| | - M. A. Fabbri
- Medical Oncology Unit, Belcolle Hospital, Strada Sammartinese 1, 01100 Viterbo, Italy
| | - M. A. Giampaolo
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Mentuccia
- Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy
| | - L. Di Lauro
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - P. Vici
- Medical Oncology B Division, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| |
Collapse
|
14
|
Grande R, Cianci G, Sperduti I, Gemma D, Gelibter A, Giampaolo M, Mentuccia L, Narducci F, Magnolfi E, Gamucci T. FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Grande R, Cianci G, Grassi G, Sperduti I, Narducci F, Gelibter A, Nuzzo C, Mentuccia L, Giampaolo M, Gamucci T. 6056 Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer (mCRC) patients (pts): is efficacy mantained? EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71151-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
16
|
Gamucci T, Narducci F, Sperduti I, Mentuccia L, Trapasso T, Magnolfi E, Grande R, Cianci G, Gemma D, Trombetta G. Evaluation of the Edmonton Symptoms Assesment Scale (ESAS) symptoms improvement (SI) assessment as a prognostic factor for survival in advanced cancer patients (pts) undergoing palliative care (PC): An observational prospective study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9591 Background: ESAS is a validated tool for physical symptoms assessment in PC practice which evaluates symptoms through a numeric scale ( 0–10). The use of SI as a prognostic factor is controversial. To this purpose, an observational prospective study in advanced cancer pts previously treated with anti-cancer treatments and now undergoing only PC was conducted. Methods: Pts were considered eligible if no longer able to receive any anticancer treatment; they were scheduled to undergo ESAS assessment: 1) at the hospitalization time-point (TH); 2) at the hospital discharge time-point (TD). Symptoms’ scores were divided into 3 severity-classes (SC): mild (0–3, MI), moderate (4–6, MO) and severe (≥7, S). Differences across symptoms’ classes between TH and TD was analyzed with the paired-data McNemar-test, according to tumor types. KM method was used for survival calculation, according to ESAS score classes, and logrank test for curves comparison. Uni/multi-variate survival analysis including age, sex, tumour, symptoms number and score class, PaP (Palliative Prognostic)-score, KPS, were carried out using the Cox regression model. Results: ESAS was administered to 68 pts, gastrointesinal (GI)/lung (NSCLC): 39/29, median age: 69-yrs, KPS ≤50/>50: 27 (39.7 %)/ 41 (60.3%), PaP-score A/B/C: 26 (38.2%)/37 (54.4%)/C (7.4%). A statistically significant reduction of S-SC rates was observed, as shown in the Table . SI correlates with survival improvement: PaP score (HR 2.95, 95% CI 1.35–6.41, p=0.006) and anorexia (HR 3.21, 95% CI 1.33–7.72, p=0.009) appear to be prognostic factors for survival at the multivariate analaysis for GI pts; asthenia is the only significant variable (HR 5.11 CI 95% 1.86–14.03, p=.0.002) for NSCLC pts. Conclusions: SI according to ESAS after PC treatment represents an important prognostic factor for survival in pts no longer suitable to receive any anticancer active therapies. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Gamucci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - F. Narducci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - I. Sperduti
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - L. Mentuccia
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - T. Trapasso
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - E. Magnolfi
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - R. Grande
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - G. Cianci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - D. Gemma
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - G. Trombetta
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
17
|
Bracarda S, Porta C, Boni C, Santoro A, Artioli F, Contu A, Mentuccia L, Gasparro D, Caserta C, De Angelis V. SORAFENIB PLUS INTERFERON-α2A IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM RAPSODY (GOIRC STUDY 0681), A RANDOMISED PROSPECTIVE PHASE II TRIAL OF TWO DIFFERENT TREATMENT SCHEDULES. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/s1569-9056(08)60694-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Loupakis F, Masi G, Bursi S, Picone V, Mentuccia L, Granetto C, Fea E, Murr R, Antonuzzo A, Falcone A. Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15059 Background: 5FU in combination with P can be considered a standard treatment for MGC. Ir and T are active agents with not complete cross-resistance with P and 5FU. The combination of Ir or T with P and 5FU is feasible but with substantial toxicities. A different way to include Ir and T in the first-line treatment of MGC is to use them sequentially to a P and 5FU containing regimen. Methods: we conducted a phase II study of first-line sequential chemotherapy in MGC pts with measurable disease (RECIST criteria). Treatment consisted of: 3 cycles of PFL (biweekly P 50 mg/sqm d1, LV 200 mg/sqm d1 and 5FU 3200 mg/sqm 48-h c.i. starting on d1) followed by 3 cycles of IrFL (biweekly Ir 180 mg/sqm d1 and 5FU/LV) followed by 3 cycles of TFL (biweekly T 50 mg/sqm d1 and 5FU/LV). Evaluation of disease was performed every 3 cycles. Results: 46 pts have been enrolled. Pts characteristics are: median age = 60 years (37–75), M/F = 36/10, sites of disease (single/multiple) 9/37, ECOG PS 0/1 = 27/19. Treatment was well tolerated. Grade 3–4 non-haematological toxicities were: diarrhea in 2,5% pts with PFL; diarrhea and asthenia in 2,5% and stomatitis in 5% pts with IrFL; stomatitis in 5,7% pts with TFL. Grade 3/4 neutropenia was observed in 14% pts with PFL, 15% with IrFL and 22,9% pts with TFL. Nor febrile neutropenia neither toxic deaths have occurred. Two pts had not evaluable disease and 6 are still receiving treatment. We observed 1 CR and 8 PR with PFL (RR 24%) among the 38 evaluable pts. IrFL improved responses in 10 pts while 4 pts progressed and TFL further improved responses in 6 pts while 5 pts progressed. Response rate at the end of the planned 9 cycles was 40% (4 CR, 11 PR; 95% CI 25–58%). At a median follow-up of 15.5 mos median TTP is 6.8 mos and median OS is 13.5 mos. Conclusions: this sequential treatment is feasible with a very favourable safety profile and produces encouraging results in terms of activity and efficacy in a population of unselected MGC patients. Final data will be presented at the meeting. Partially supported by A.R.C.O. Foundation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Loupakis
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - G. Masi
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - S. Bursi
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - V. Picone
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - L. Mentuccia
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - C. Granetto
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - E. Fea
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - R. Murr
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - A. Antonuzzo
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - A. Falcone
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| |
Collapse
|
19
|
Pollera CF, Nelli F, Gamucci T, Sperduti I, Giampaolo AM, Moscetti L, Tonini G, Mentuccia L, Nardi M, Cortesi E. Prospective evaluation of epoetin-alfa (EA) vs epoetin-beta (EB) vs darbepoetin (DE) in anemic cancer patients (pts) receiving chemotherapy (CT): Early results of an independent observational survey by the Italian ReVERTO network. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18548 Background: Direct comparison of EA vs EB vs DE has never been performed. In order to define the efficacy, impact on quality of life (QL) and pt’s preference, a prospective observational comparison of erythropoietic agents has been carried out. Methods: Anemic pts (hgb <11 gr/dL) scheduled to receive at least 3 cycles of CT were stratified according to 5 factors (platinum-based CT vs non-platinum; hgb ≤9,5 vs >9,5; PS ≤0–1 vs >1; previous CT vs upfront CT; and previous antianemic therapy vs not) and were autonomously assigned by 15 investigators to EA (3 times a week) or EB (3 times a week and only in pts receiving platinum-based CT) or DE (once a week) therapy. Efficacy by hgb level changes and transfusion needing was evaluated after each cycle of CT, QL by Fact-An questionnaire after 1 and 3 cycles of CT, and pt’s preference for standard vs weekly schedule at least once thereafter. Results: From 09/04 to 12/05 177 pts were recruited: 41%, 39% and 20% were assigned to DE, EA and EB, respectively. Severe anemia at baseline (≤9,5) was reported in 29% of pts, whereas 47% received platinum-based CT. Stratifying categories were well balanced among the treatment groups. Baseline mean hgb values were 9.7, 9.9, and 10 for DE, EA and EB, respectively. As of the general population, DE produced higher subsequent mean hgb increase in respect to EA and EB (Mean increase [gr/dL] for DE: 0.84, 1.58, 2.03; EA: 0.34, 0.84, 1.68; EB: 0.76, 1.54, 1.17). No difference was observed neither among pts receiving platinum-based CT, (mean increase: DE: 0.34, 1.76, 2.8; EA: 0.7, 1.27, 2.14; EB: 0.76, 1.54, 1.71) nor among pts with severe anemia at baseline (DE: 0.98, 2, 2.6; EA: 1.24, 1.94, 3.13; EB: 1.25, 2.25, 2.75). Transfusion needing ranged from 7% for DE to 3% for EB without any significant difference. To date 67% of pts completed at least one subsequent QL valuation, whereas 62% gave their preference for treatment schedule. Conclusions: Early results of our prospective analysis show that antianemic therapy with D is at least as effective as standard schedule of EA or EB. Efficacy of DE seems confirmed in pts with bad prognostic categories for anemia. Major data on QL and pt’s preference will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. F. Pollera
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - F. Nelli
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - T. Gamucci
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - I. Sperduti
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - A. M. Giampaolo
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - L. Moscetti
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - G. Tonini
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - L. Mentuccia
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - M. Nardi
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - E. Cortesi
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| |
Collapse
|